Tony Esposito will step down Friday as the Pennsylvania-based health system contends with uncertainty about its future.
Crozer CEO steps down as health system fights to remain open Read More »
Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.
Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II Read More »
Despite making an unsolicited bid for gene therapy maker bluebird bio, Ayrmid failed to deliver a binding offer after weeks of due diligence. Bluebird’s board recommended that it go with Carlyle and SK Capital Partner’s original offer to take the company private for $30 million.
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer Read More »
Analysts are “cautiously optimistic” about Trump’s executive order, noting that changes to the IRA drug price negotiation program will still require Congressional action before being implemented.
‘Finally, Some Good News’: Trump Signals Support for Removing IRA’s Pill Penalty Read More »
The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.
US launches probe that could set stage for pharma tariffs Read More »
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission Read More »
The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of symptoms.
Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year Read More »
El Triásico es uno de los periodos geológicos más importantes en la evolución de la vida en la Tierra. Tras producirse, hace 252 millones de años, la mayor extinción masiva de todas las conocidas de la historia de la vida en la Tierra, no solo surgieron los …
Unos científicos han creado dos nuevas herramientas (o “tijeras”) de edición genética con características únicas, inspiradas en elementos genéticos microbianos de las profundidades oceánicas. El logro es obra de un equipo del Inst …
Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed Read More »
